patented drugs

Printer-friendly version
Trump executive order may limit access to prescription drugs in Canada

Drug manufacturers may forgo sales in Canada to increase average reference prices.

Printer-friendly version
Ottawa’s changes to drug-pricing will deny some Canadians potentially lifesaving drugs

Forcing manufacturers of high-cost drugs to reduce their prices by up to 80 per cent is unsustainable.

Printer-friendly version

Pharmaceutical manufacturers take on a significant investment risk to develop new drugs.

Printer-friendly version
The opposition of the two U.S. presidential candidates to the Trans-Pacific Partnership (TPP) threatens progress on trade issues including intellectual property protection.